Corcept Therapeutics Inc. insider trading
CORTfinancial statementsForm 4 filings on EDGAR509 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at Corcept Therapeutics Inc. bought $0 of stock in the open market, and 8 sold $42M. Officers and directors accounted for $0 of purchases and $42M of sales. The last reported transaction was an open-market sale by Wilson James N on October 15, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 16, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $42MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
509 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Wilson James N | Director | open-market sale10b5-1indirect | 6,654 | $114.48 | $762K | 1M | Oct 16, 2026 |
| Oct 15, 2026 | Wilson James N | Director | open-market sale10b5-1indirect | 3,046 | $115.39 | $351K | 1M | Oct 16, 2026 |
| Oct 15, 2026 | Wilson James N | Director | open-market sale10b5-1indirect | 300 | $116.30 | $35K | 1M | Oct 16, 2026 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | option exercise | 8,333 | $21.63 | $180K | 12,279 | Oct 5, 2026 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 1,100 | $114.52 | $126K | 11,179 | Oct 5, 2026 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 2,086 | $115.73 | $241K | 9,093 | Oct 5, 2026 |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 5,147 | $116.58 | $600K | 3,946 | Oct 5, 2026 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | option exercise | 3,357 | $13.56 | $46K | 9,040 | Oct 5, 2026 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | option exercise | 5,833 | $19.26 | $112K | 14,873 | Oct 5, 2026 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | open-market sale10b5-1 | 4,446 | $115.70 | $514K | 10,427 | Oct 5, 2026 |
| Oct 2, 2026 | Lyon Joseph Douglas | See Remarks | open-market sale10b5-1 | 4,744 | $116.54 | $553K | 5,683 | Oct 5, 2026 |
| Oct 2, 2026 | Maduck Sean | See Remarks | option exercise | 24,587 | $8.27 | $203K | 34,525 | Oct 5, 2026 |
| Oct 2, 2026 | Maduck Sean | See Remarks | open-market sale10b5-1 | 15,843 | $116.12 | $2M | 18,682 | Oct 5, 2026 |
| Oct 2, 2026 | Maduck Sean | See Remarks | open-market sale10b5-1 | 8,744 | $116.55 | $1M | 9,938 | Oct 5, 2026 |
| Oct 1, 2026 | Lyon Joseph Douglas | See Remarks | option exercise | 810 | $13.56 | $11K | 6,493 | Oct 5, 2026 |
| Oct 1, 2026 | Lyon Joseph Douglas | See Remarks | open-market sale10b5-1 | 810 | $115.40 | $93K | 5,683 | Oct 5, 2026 |
| Oct 1, 2026 | Maduck Sean | See Remarks | option exercise | 413 | $8.27 | $3K | 10,351 | Oct 5, 2026 |
| Oct 1, 2026 | Maduck Sean | See Remarks | open-market sale10b5-1 | 413 | $115.54 | $48K | 9,938 | Oct 5, 2026 |
| Sep 24, 2026 | Robb Gary Charles | Chief Business Officer | gift | 17,100 | $0.00 | — | 14,056 | Sep 28, 2026 |
| Sep 24, 2026 | Robb Gary Charles | Chief Business Officer | giftindirect | 5,000 | $0.00 | — | 20,571 | Sep 28, 2026 |
| Sep 17, 2026 | Robb Gary Charles | Chief Business Officer | option exercise | 17,493 | $8.27 | $145K | 31,156 | Sep 18, 2026 |
| Sep 16, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 296 | $100.82 | $30K | 3,946 | Sep 18, 2026 |
| Sep 15, 2026 | Wilson James N | Director | open-market sale10b5-1indirect | 6,800 | $110.27 | $750K | 1M | Sep 16, 2026 |
| Sep 15, 2026 | Wilson James N | Director | open-market sale10b5-1indirect | 400 | $110.84 | $44K | 1M | Sep 16, 2026 |
| Sep 15, 2026 | Wilson James N | Director | open-market sale10b5-1indirect | 2,800 | $111.70 | $313K | 1M | Sep 16, 2026 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | option exercise | 2,596 | $11.35 | $29K | 8,279 | Sep 16, 2026 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | option exercise | 7,404 | $13.56 | $100K | 15,683 | Sep 16, 2026 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | open-market sale10b5-1 | 7,812 | $113.32 | $885K | 7,871 | Sep 16, 2026 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | open-market sale10b5-1 | 2,188 | $114.12 | $250K | 5,683 | Sep 16, 2026 |
| Sep 2, 2026 | Maduck Sean | See Remarks | tax withholding | 117 | $113.38 | $13K | 9,938 | Sep 3, 2026 |
| Sep 2, 2026 | Mokari Atabak | Chief Financial Officer | tax withholding | 102 | $113.38 | $12K | 16,304 | Sep 3, 2026 |
| Sep 2, 2026 | Robb Gary Charles | Chief Business Officer | tax withholding | 91 | $113.38 | $10K | 13,663 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | tax withholding | 102 | $113.38 | $12K | 4,242 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | option exercise | 58,333 | $21.63 | $1M | 62,575 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 23,600 | $109.35 | $3M | 38,975 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 23,770 | $110.70 | $3M | 15,205 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 1,537 | $111.37 | $171K | 13,668 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 974 | $112.40 | $109K | 12,694 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 1,606 | $113.72 | $183K | 11,088 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 5,621 | $114.58 | $644K | 5,467 | Sep 3, 2026 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | open-market sale10b5-1 | 1,225 | $115.44 | $141K | 4,242 | Sep 3, 2026 |
| Sep 2, 2026 | Lyon Joseph Douglas | See Remarks | tax withholding | 72 | $113.38 | $8K | 5,683 | Sep 3, 2026 |
| Sep 1, 2026 | Guyer William | Chief Development Officer | award | 164 | $113.38 | $19K | 4,149 | Sep 3, 2026 |
| Sep 1, 2026 | Guyer William | Chief Development Officer | award | 164 | $0.00 | — | 4,313 | Sep 3, 2026 |
| Sep 1, 2026 | Maduck Sean | See Remarks | option exercise | 25,000 | $8.27 | $207K | 34,755 | Sep 3, 2026 |
| Sep 1, 2026 | Maduck Sean | See Remarks | open-market sale10b5-1 | 11,730 | $113.94 | $1M | 23,025 | Sep 3, 2026 |
| Sep 1, 2026 | Maduck Sean | See Remarks | open-market sale10b5-1 | 10,989 | $114.71 | $1M | 12,036 | Sep 3, 2026 |
| Sep 1, 2026 | Maduck Sean | See Remarks | open-market sale10b5-1 | 2,281 | $115.61 | $264K | 9,755 | Sep 3, 2026 |
| Sep 1, 2026 | Maduck Sean | See Remarks | award | 150 | $113.38 | $17K | 9,905 | Sep 3, 2026 |
| Sep 1, 2026 | Maduck Sean | See Remarks | award | 150 | $0.00 | — | 10,055 | Sep 3, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Maduck Sean | See Remarks | Oct 2, 2026 | option exercise | 34,525 | — | $24M (20) | 20 of 20 |
| Mokari Atabak | Chief Financial Officer | Sep 2, 2026 | tax withholding | 16,304 | — | $19M (22) | 22 of 22 |
| Mahoney David L | Director | Aug 18, 2026 | open-market sale | 30,000 | — | $14M (5) | 4 of 5 |
| Guyer William | Chief Development Officer | Sep 1, 2026 | award | 4,149 | — | $13M (19) | 17 of 19 |
| Belanoff Joseph K | Chief Executive Officer, Director | Jun 1, 2026 | open-market sale | 243,154 | — | $10M (8) | 8 of 8 |
| Vieira Roberto Wandenkolk | President, Oncology | Oct 2, 2026 | option exercise | 12,279 | — | $7M (11) | 11 of 11 |
| Wilson James N | Director | Oct 15, 2026 | open-market sale | 0 | — | $5M (15) | 15 of 15 |
| Lyon Joseph Douglas | See Remarks | Oct 2, 2026 | option exercise | 9,040 | — | $4M (9) | 7 of 9 |
| Baker G Leonard JR | Director | Mar 17, 2026 | open-market buy | 1M | $3M (2) | — | — |
| Park Kimberly | Director | Aug 26, 2026 | option exercise | 30,000 | — | $3M (1) | 0 of 1 |
| Robb Gary Charles | Chief Business Officer | Sep 24, 2026 | gift | 14,056 | — | $1M (1) | 0 of 1 |
| Swisher Daniel N JR | Director | Oct 10, 2025 | open-market sale | 0 | — | — | — |
| Hunt Hazel | Chief Scientific Officer | Feb 9, 2026 | option exercise | 333,405 | — | — | — |
| Cannon Gillian | Director | Sep 10, 2025 | gift | 0 | — | — | — |
Questions
Are Corcept Therapeutics Inc. insiders buying or selling?
Over the twelve months to November 3, 2026, 10 insiders at Corcept Therapeutics Inc. sold $102M of stock in the open market, all by officers and directors, and 1 insider bought $3M, all by officers and directors. Net, insiders sold $98M. Only open-market purchases and sales are counted.
Who sold the most Corcept Therapeutics Inc. stock in the last year?
Maduck Sean (See Remarks) sold $24M in 20 open-market sales over the twelve months to November 3, 2026.
Do Corcept Therapeutics Inc. executives sell under 10b5-1 plans?
104 of the 111 open-market sales in the last twelve months (94%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Corcept Therapeutics Inc.
- Corcept Therapeutics Inc. financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.